Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

Several other equities analysts also recently weighed in on the company. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $18.00 target price on shares of Trillium Therapeutics in a research report on Friday, June 9th. Finally, HC Wainwright started coverage on Trillium Therapeutics in a research report on Monday, July 17th. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Trillium Therapeutics currently has an average rating of “Buy” and a consensus price target of $14.95.

Shares of Trillium Therapeutics (NASDAQ TRIL) opened at 5.10 on Tuesday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $17.70. The company has a 50-day moving average of $4.65 and a 200-day moving average of $5.27. The stock’s market capitalization is $55.05 million.

TRADEMARK VIOLATION NOTICE: “Trillium Therapeutics Inc. (TRIL) Rating Increased to Hold at Zacks Investment Research” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/21/trillium-therapeutics-inc-tril-rating-increased-to-hold-at-zacks-investment-research.html.

Several institutional investors have recently made changes to their positions in TRIL. Wells Fargo & Company MN grew its position in shares of Trillium Therapeutics by 34.1% during the first quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock worth $109,000 after buying an additional 4,500 shares in the last quarter. Creative Planning grew its position in shares of Trillium Therapeutics by 1.1% during the second quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock worth $116,000 after buying an additional 300 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Trillium Therapeutics during the second quarter worth about $128,000. K2 Principal Fund L.P. acquired a new position in shares of Trillium Therapeutics during the second quarter worth about $264,000. Finally, Victory Capital Management Inc. grew its position in shares of Trillium Therapeutics by 40.0% during the first quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock worth $479,000 after buying an additional 22,171 shares in the last quarter. 47.97% of the stock is owned by institutional investors and hedge funds.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.